Vladimir Cmiljanović

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Florent Beaufils, Nataša Cmiljanović, Vladimir Cmiljanović et al. · Journal of Medicinal Chemistry · 2017 · 132 citations · Full text

Chemoprevention Strategy, Immunology, Clinical Candidate +19

Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors

Romina Marone, Dominik Erhart, Ann C. Mertz et al. · Molecular Cancer Research · 2009 · 124 citations

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy

Chiara Tarantelli, Eugenio Gaudio, Alberto J. Arribas et al. · Clinical Cancer Research · 2017 · 117 citations

Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

Thomas Bohnacker, A.E. Prota, Florent Beaufils et al. · Nature Communications · 2017 · 113 citations · Full text

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

Andreas Wicki, Nicholas F. Brown, Alexandros Xyrafas et al. · European Journal of Cancer · 2018 · 62 citations

Medicine, Pharmacology, Pharmacotherapy +8